43 results about "Anti-angiogenesis agent" patented technology

A method for treating diseases associated with abnormal cell proliferation comprises delivering to a patient in need of treatment a compound selected from the group consisting of 20(S)-camptothecin, analog of 20(S)-camptothecin, derivative of 20(S)-camptothecin, prodrug of 20(S)-camptothecin, and pharmaceutically active metabolite of 20(S)-camptothecin, in combination with an effective amount of one or more agents selected from the group consisting of alkylating agent, antibiotic agent, an alkylating agent, antibiotic agent, antimetabolic agent, hormonal agent, plant-derived agent, anti-angiogenesis agent and biologic agent. The method can be used to treat benign tumors, malignant or metastatic tumors, leukemia and diseases associated with abnormal angiogenesis.

α,β-Unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides of Formula I:

wherein R¹, R², M¹, M², L, E¹, E², Q¹, Q² and n are as defined herein, are useful as anti-angiogenesis agents, as agents for treatment of age related senile dementia, and as antiproliferative agents including, for example, as anticancer agents.

Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and a bisphosphonate bone targeting agent, and processes of preparing same, are disclosed.

Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of bone related disorders are also disclosed.

The invention provides an agent that reduces the expression of Gα₁₂ or Gα₁₃ polypeptide, as well as an agent that enhances G protein Gα₁₂ or Gα₁₃ expression and/or activity. An agent of the invention may be used to decrease or increase G protein Gα₁₂ or Gα₁₃ expression and/or activity thereby to treat or prevent the onset of a disease or condition associated with Gα₁₂ or Gα₁₃ expression and/or activity. The invention also provides a method for screening for an anti-cancer or anti-angiogenesis agent, as well as an agent that promotes angiogenesis.

The disclosure provides compositions and methods for treating cancers. The method comprises administering an anti-angiogenesis agent and an OX40 binding agonist.

The invention discloses a sesterterpene compound 1-34 and a medicinal composition taking the compound as an active ingredient. A preparation method of the sesterterpene compound 1-34 comprises the following steps of: performing direct cold soaking or thermal reflux extraction on leaves or flowers or stems of labiatae tripterygium hypoglaucum plant with an organic solvent, i.e., petroleum ether or n-hexane or cyclohexane or chloroform or acetone or methanol or ethanol; or performing cold soaking or thermal reflux extraction on the organic solvent, and extracting with ethyl acetate to obtain a total extract; and repeatedly performing column chromatography on the total extract to obtain the compound. The compound is applied to preparation of an anti-angiogenesis agent, an anti-prolyl endopeptidase agent, an antibacterial agent, an anti-feedant and a flavor: the compound has high antibiotic activity when being applied to a substrate or a group in an amount of 10-1,000muM and being optionally combined with a carrier and/or a medium; the compound has high antifeedant activity when being applied to a substrate or a group in an amount of 0.005-10muM/cm<2> and being optionally combined with a carrier and/or a medium; and the compound has clear flavor and high hair permeability, can be used for improving the hair flavor when used for blending, has the characteristic of unique flavor, is clear and pure, can be used for covering bad flavors of surfactant substrate raw materials, and is safe for a long time.

Conjugates of hydroxypropyl methacrylamide (HPMA)-derived copolymers having attached thereto TNP-470 and a high load (e.g., higher than 3 mol %) of alendronate (ALN), and processes of preparing same are disclosed. Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and an oligoaspartate bone targeting agent, and processes of preparing same, are further disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment and monitoring of bone related disorders are also disclosed.

The present invention relates to methods and devices for delivering one or more biologically active agents, particularly therapeutic agents, the intradermal compartment of a subject's skin. The present invention provides an improved method of delivery of biologically active agents, such as therapeutic agents, through lymphatic vasculature accessed by intradermal delivery. Therapeutic agents to be delivered in accordance with the present invention include, but are not limited ton antineoplastic agents, chemotherapeutic agents, antibodies, antibiotics, anti-angiogenesis agents, anti-inflammatory agents, and immunotherapeutic agents. Therapeutic agents delivered in accordance with the present invention have improved bioavailability, including improved systemic distribution and improved delivery to particular tissues. Therapeutic agents, delivered in accordance with the methods of the invention have an improved clinical utility and therapeutic efficacy relative to other drug delivery methods, including intraperitoneal, intramuscular and subcutaneous delivery. The methods of the present invention provide benefits and improvements over convention drug delivery methods including dose sparing, increased drug efficacy, reduced side effects, reduced metastatic potential and prolonged survival.

Resistance of randomly dispersed and oxygen-starved lung tumor cells to chemo- and radiotherapy constitutes the vast majority recurrences and death from lung cancer. We use sickle cells derived from humans with sickle cell anemia to target oxygen-deprived tumor cells that persist and multiply after conventional treatment. Transfused sickle cells selectively occluded tumor microvessels and shut down blood flow to these oxygen-deprived pockets leading to tumor cell death and complete shrinkage of aggressive lung tumors. Combining the sickle cells with a vascular disrupting agents and radiation injure and narrow tumor blood vessels, amplified the scale of sickle cell-induced blood vessel closure and tumor cell killing. The strength of the tumor killing produced by this combination exceeded that of either agent alone or combined with conventional anti-angiogenics, chemotherapy or radiation. Combinatorial sickle cells-Combretastatin treatment thereby constitutes a major advance toward eradicating treatment-resistant tumor cells and reducing the frequency of lung cancer recurrence.